The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
No doubt they will need to rationalise it all. Reflect the revamped strategy and provide some forward looking statements. We may learn a nice thing or two from commercial successes. Last TU was more than 6months ago...
Just watched the recording. Like you mentioned there seems to be a lot of untapped potential for ImmunoInsights. Slim competition and a big addressable market especially when the Big Pharmas/and Biopharmas etc are seeing value of such antibody profiling services during the CRO cycles. I think that this address to the investors was important to win back some confidence and I thank Martin for delivering the message to the investors that a more predictable growth and revenue is needed an this is being implemented now too. I hope this also means that we can get some guidance in the coming reports on what to expect. You see these days, much of what is being invested is based on future growth. And without any reliable prediction or forecast all this goes out the window. Hence why ONC trades at these levels. Growth is baked in to the current SP at the most conservative level...
Looking forward to the year ahead with this business.
Thanks Doc....I will review the recording too when I get a chance today. It all sounds so promising. Oh how I wish today was my first day to know ONC. What an SP indeed. Similar to yourself I was bought in with Early-CDT, first but around the ECLS study. I think that is why the asset sale was a bit of a punch to the gut. But it seems like we should be on the up soon again.
I am actually for once super optimistic. Think we must have hit the bottom.
https://www. v o x markets.co.uk/articles/oncimmune-shifts-strategy-to-accelerate-commercial-expansion-871f174/
Sorry....CAPEX reduced due to sale of assets to Biodesix and Freenome whilst longer term revenue secured at least for next couple of years. OPEX I think overall down due tonlower overheads. Not sure how the employee salaries play into this number as many expensive new hires incl execs but also terminated contracts. More sales improves bottom line as more lab capacity used. I feel it is currently heavily under capacity (probably around 20-30%)?
Interesting updates. You can tell that the leadership team is focussing on establishing sales structures that cater for different customer segments but as it looks all gearing to supporting long term partnerships, becoming an essential partner in CRO cycles and generating revenue through existing and new long term MSAs. CAPEX significantly reduced as the upfront lift of establishing a competent sales team in US and UK was done over the last couple of years and with that getting these key account MSA's signed. Hopefully we can see demand picking up and and lab facilities being used at higher capacity.
New strategy means some more from the old guard are leaving and the focus seems clearly on generating long term sustainable revenue and doing more of the above.
I suppose this years number will be a bit skewed again because of the Onc Ltd. Balances being included still. Will be interesting to read in the coming weeks/months.
100%. There is probably a lot of stuff going on in the background.
1. On boarding - getting familiar with ONC business
2. Connecting with existing customers and building relationships
3. Introducing other exec relationships to ONC.
4. Defining sales strategy and building supportive business development and sales execution strategy
5. Establish roadmap for sales, lab capacity, digitalisation etc.
6. Crush it
But you are so right - it's time we hear something. It has been quite a number of mo ths since meaningful trade updates were delivered. Perhaps some information was muddied by the sale of ONC non core assets (Oncimmune Ltd.).
But I will be cup half full today. They are working out a brilliant pitch to the investor group that will have us frothing from the mouth. I do think that Martin brings the credentials both in Corporate Finance and Biopharma . I hope he uses his CF experience not for an immediate takeover case ^^. Like you mentioned though I also think it would be nonsensical at this stage especially after already selling a big chunk of the business for peanuts.
According to the AIM rules companies are obliged to report annual financial within 6 months of the end of the fiscal year. No holding my breath. With CFO gone and new Head of Finance I am sure this could stretch out another month or two.
Also just to add that i am aware that i am barking up the wrong tree, when complaining or commenting here. I also know that whilst may investment may be bigger than that of Barclays, it may be dwarfed by that of HSBC.
Balderton Capital III,LP 6,813,196shares 9.19%
Blind Trust (Richard Sharp) 4,891,444shares 6.60%
Credit Suisse 4,326,454shares 5.84%
BNP Paribas Arbitrage 3,850,408shares 5.19%
Chelverton Asset Management 4,000,000shares 5.40%
Dr Adam M Hill 3,689,734shares 4.81%
Genostics Company Ltd 3,335,659shares 4.50%
Mr Timothy Brian Bunting 4,856,717shares 6.55%
Hargreaves Lansdown Asset Management 2,717,717shares 3.67%
HSBC Holdings Plc 2,539,848shares 3.43%
state of affairs....
Yea I know... itll take time... i just wished id know how to best spend the time as what i have given to ONC has been consumed without return of value, instead with return of significant worry and insecurity.
My nightmare would be if they'd turned around and said they just decided it was not worth the husstle and they sold the business - silently working out a deal in the background. It would be upset about the years gone by and the missed opportunity
My hope on the flip side is that they are sitting around a table and working out a simple plan to go from here to the moon. The rocket (ImmunoInsights platform) is there, we already had a few launches with mixed results. Neil Armstrong (A. Hill) and Buzz Aldrin (M. Hall) are now both not there anymore, + they never really landed on the moon to begin with..... and ONC have a fearless team that has hopefully been made just as motivated and excited about pushing through this mess through company share options.
Let's do this Martin and team. Its a straight line and it should be just straight forward. ONC should be a money pit. We should be at full capacity, not knowing how to fulfil all the orders. Occasionally ONC should be throwing up large sums of hard stinking cash..and leave that for us to feed on....
Looking forward to a Paul Hill / Martin Gouldstone interview in the near term. Might be further down the line to allow Martin to get a real grip on the business. We are all eagerly awaiting something :) I am also slightly nervous. When you have been kicked in the teeth as often as I have with ONC and other shares, you grow weary of any financial report when you have a steak ^^
I was not going to jump to the conclusion that they are fake but it sure looks like it.
Pumping money only to bring down my average. 35p would be a nice little milestone and still a road and journey ahead. The next investments need to be planned thoroughly and executed with distinction. The company needs to demonstrate that they can stabilise their expenses and grow revenue. Hiring a bunch of new executives surely won't be cheap for the business either.